After a CDK4/6 Inhibitor: State of the Art in Hormone Receptor-Positive Metastatic Breast Cancer

By afschroeder • June 21, 2025

Teysir J, Lloyd MR, Alkassis S, Callahan RD, Fairley R, Wander SA, Bardia A, Jhaveri KL. After a CDK4/6 Inhibitor: State of the Art in Hormone Receptor-Positive Metastatic Breast Cancer. Am Soc Clin Oncol Educ Book. 2025 Jun;45(3):e473372. doi: 10.1200/EDBK-25-473372. Epub 2025 Jun 20. PMID: 40540707.

Tags: Hematology/Oncology, Publications

Pooled Analysis of the SOLAR and SATURN Clinical Trials Comparing Progression of Synchronous Versus Metachronous Prostate-specific Membrane Antigen-defined Oligometastatic Prostate Cancer Following Systemic and Tumor-directed Therapy

Juarez Casillas JE, Nikitas J, Rettig MB, Reiter RE, Lee A, Steinberg ML, Valle L, Kalbasi TR, Calais J, Czernin J, Eala MA, Tsai S,[...]

Role of immunotherapy in early breast cancer: past, present, and future

Britten K, Bardia A, McAndrew N. Role of immunotherapy in early breast cancer: past, present, and future. Target Oncol. 2025 Jun 20. doi: 10.1007/s11523-025-01157-1. Epub[...]

A Rare Presentation of Priapism From Pegylated Filgrastim During Treatment of Urothelial Cancer in an African-American Patient With Sickle Cell Trait

Kathuria-Prakash N, Damron L, Hernandez SC, Hart SD, Drakaki A. A Rare Presentation of Priapism From Pegylated Filgrastim During Treatment of Urothelial Cancer in an[...]